Literature DB >> 16339704

Preclinical and clinical development of deferitrin, a novel, orally available iron chelator.

Joanne M Donovan1, Melissa Plone, Rafif Dagher, Mark Bree, Judith Marquis.   

Abstract

Deferitrin, a novel, orally available iron chelator, is in the early stage of clinical development for the treatment of chronic iron overload due to transfusional therapy. Preclinical pharmacology studies demonstrate iron excretion largely by the fecal route. Initial clinical studies have shown deferitrin to be well absorbed. Further clinical studies are ongoing to determine the efficiency and safety of deferitrin.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16339704     DOI: 10.1196/annals.1345.071

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  6 in total

1.  Synthesis and characterization of a triazine dendrimer that sequesters iron(III) using 12 desferrioxamine B groups.

Authors:  Jongdoo Lim; Vincent J Venditto; Eric E Simanek
Journal:  Bioorg Med Chem       Date:  2010-05-20       Impact factor: 3.641

Review 2.  Optimal management strategies for chronic iron overload.

Authors:  James C Barton
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Metabolically programmed iron chelators.

Authors:  Raymond J Bergeron; Neelam Bharti; James S McManis; Jan Wiegand
Journal:  Bioorg Med Chem       Date:  2015-06-29       Impact factor: 3.641

Review 4.  Modification of fibrin structure as a possible cause of thrombolytic resistance.

Authors:  Boguslaw Lipinski
Journal:  J Thromb Thrombolysis       Date:  2010-04       Impact factor: 2.300

5.  Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective.

Authors:  Renzo Galanello
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

Review 6.  Desferrithiocin: a search for clinically effective iron chelators.

Authors:  Raymond J Bergeron; Jan Wiegand; James S McManis; Neelam Bharti
Journal:  J Med Chem       Date:  2014-09-10       Impact factor: 7.446

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.